Updated: 2005-11-29
BACKGROUND:
A statement of the country of origin on the labeling of imported foods is not required by the Federal Food, Drug, & Cosmetic Act. This is a requirement of the U.S. Customs *and Border Protection (CBP)* as authorized by the Tariff Act of 1930 and CPB regulations (19 USC 1304(a) and 19 CFR Part 134).
Repackers are required by *CBP* to mark containers of repackaged imports with the English name of the country of origin. In the event that further reprocessing or material added to the article in another country results in a "substantial transformation" of the product, the other country becomes the country of origin within the meaning of *CBP's* labeling requirements, 19 CFR 134.1(b) and 134.11. As a result of *CBP’s* seizure actions and other regulatory follow-up involving imported shrimp that was peeled, deveined, and repacked in the United States and labeled as a product of the U.S. FDA received congressional, industry, and field inquiries regarding FDA's jurisdiction and policy on country of origin labeling for this product. *CBP* considers that peeling, deveining, and repacking is not a "substantial transformation" of the product, sufficient to permit the shrimp to be declared as a product of the U.S., within the meaning of *CBP’s* laws and regulations.
POLICY:
Food labeling statements regarding geographical origin must not be false or misleading in any particular. FDA's policy prohibiting false or misleading labeling of food applies equally to imported and domestic products (*section 403(a)(1)* and 21 CFR 101.18).
It is possible that a violation of *CBP’s* requirement concerning country of origin labeling, whether by omission or deviation, could also result in false or misleading labeling that violates the FFD&C Act and FDA regulations.
Examples:
FDA's policy regarding false or misleading country of origin labeling is to defer to *CBP*. Such labeling is also a violation of the Tariff Act of 1930, which is enforced by *CBP*, and *CBP* can generally deal with this problem more efficiently than FDA.
REGULATORY ACTION GUIDANCE:
Information acquired by FDA personnel regarding false or misleading country of origin labeling should be transmitted by the district to the local *CBP* office for their consideration, together with offers of FDA cooperation in the matter and a request that the district be advised of any regulatory follow-up by *CBP*.
*Material between asterisks is new or revised*
Issued: 10/1/80
Revised: 6/30/89, 5/2005